INTRODUCTION

Canada
• The pan-Canadian Oncology Drug Review (pCODR), assesses the clinical evidence and cost-effectiveness of new cancer drugs and provide recommendations to the provinces (except Québec) and territories to guide their drug funding decisions.
• To our knowledge, globally, pCODR is the only national cancer-specific agency providing recommendations on new cancer drugs to decision makers.
Australia
• The Pharmaceutical Benefits Advisory Committee (PBAC) provides recommendations to the Minister of Health regarding which drugs and medicinal preparations should be subsidized on the Pharmaceutical Benefits Scheme (PBS), based on clinical effectiveness, safety and cost-effectiveness of a proposed benefit compared to alternative therapies.
Sweden
• The Dental and Pharmaceutical Benefits Agency (Tandvårds-och läkemedelsför-månsverket), or TLV, makes national pricing and reimbursement recommendations on which pharmaceuticals and health technologies should be covered by the Pharmaceutical Benefit Scheme, based on clinical-and cost-effectiveness.
United Kingdom
• The National Institute for Health and Care Excellence (NICE), issues guidance to the National Health Service (NHS) on the use of selected new and established health technologies, based on clinical effectiveness, safety and cost-effectiveness relative to established standards of care.
RESULTS
Summary of pCODR Recommendations:
• As of 28 April 2014, 32 oncology drug submissions, covering 38 indications received a final recommendation.
• Of these 38 indications receiving final decisions, 15 indications were in common with PBAC, 9 with TLV, and 13 with NICE.
OBJECTIVE
• The objective of this study was to compare pCODR recommendations to those made in other global markets in order to identify similarities/differences and trends associated with positive and negative recommendations
RESULTS
METHODS
• 
CONCLUSIONS
• The reviews and recommendations by pCODR, PBAC, TLV and NICE, for all included products reflected significant agreement in terms of overall clinical benefit and cost-effectiveness.
• The discordance between recommendations in most cases reflects differences in the recommendation processes/options rather than a difference in perceived value.
-For example, pCODR frequently provides a positive recommendation for a product with acceptable clinical benefit conditional on improved costeffectiveness (assumed to be achieved through price discounts or risk sharing). However, the degree of improvement in cost-effectiveness (and the implied price discount) is not specified; instead it is negotiated by the manufacturers with the provincial reimbursement bodies.
-Within the sample studied, TLV, PBAC and NICE have less frequently issued positive recommendations conditional on improvements in cost-effectiveness, risk sharing or price discounts.
• The findings of this study are relevant to research methodologists, clinical trial designers and market access stakeholders as they provide insights into the factors that may influence reimbursement globally and should be considered in product development. 
